RxDoctor Payments Data

Ashish Verma, MD

Nephrology · Worcester, MANPI 1164620324

Payments from drug & device makers

$975in general payments, 2019–2025

Across 37 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$181
  • Calliditas Therapeutics US Inc.$157
  • Nxstage Medical, Inc.$111
  • Baxter Healthcare$100
  • Travere Therapeutics, Inc.$81
  • GSK$66
  • plus $280 from 9 others

What the payments were for

  • Food & beverage$87490%
  • Education$10110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$975 in reported general payments places this provider in the 60th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$450,772
Medicare patients
788
Services billed
6,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$255,855
JardianceEmpagliflozin125$179,191
FarxigaDapagliflozin Propanediol55$53,897
VelphoroSucroferric Oxyhydroxide15$46,336
VeltassaPatiromer Calcium Sorbitex13$13,149
Sevelamer Carbonate72$12,527
Calcitriol443$8,360
LokelmaSodium Zirconium Cyclosilicate17$8,085
Sirolimus11$6,345
Bumetanide88$5,198
Potassium Citrate ErPotassium Citrate49$3,823
Losartan Potassium282$3,343
Mycophenolate Mofetil12$2,913
Amlodipine Besylate273$2,444
Torsemide73$2,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$22$255,85513 claims
AstraZenecaFarxiga, Lokelma$181$61,98272 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 339 nephrology providers in Massachusetts.

Other nephrology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →